William Sheldon
Endocrinology, Diabetes & Metabolism · Plano, TXNPI 1386651180
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,905 of the $5,689 with a category attached, or 86.2%. 29 manufacturers reported payments, led by AstraZeneca at 26.5% of the total. Reporting peaked in 2019 at $3,491 and has fallen 96.4% since, to $125 in 2024.
Across 192 payments — averaging $29.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi-aventis U.S. LLC$1K
- Mannkind Corporation$326
- Amgen$316
- Lilly USA, LLC$313
- AbbVie$284
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$77514%
- Food & beverage$4,90586%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $1,507 |
| Sanofi-aventis U.S. LLC | 34 | $1,368 |
| Mannkind Corporation | 21 | $326 |
| Amgen | 7 | $316 |
| Lilly USA, LLC | 17 | $313 |
| AbbVie | 14 | $284 |
| Novo Nordisk | 10 | $235 |
| Radius Health, Inc. | 5 | $155 |
| IBSA Pharma Inc. | 3 | $150 |
| Amarin Pharma, Inc. | 3 | $145 |
| Boehringer Ingelheim | 8 | $123 |
| Insulet Corporation | 6 | $121 |
| Merck | 6 | $89 |
| Valeritas, Inc. | 3 | $69 |
| Dexcom, Inc. | 3 | $65 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Zealand Pharma US, Inc. | 1 | $46 |
| Corcept Therapeutics | 3 | $43 |
| Pfizer | 2 | $41 |
| Amneal Pharmaceuticals LLC | 3 | $41 |
| Kvk-tech, Inc. | 3 | $34 |
| Antares Pharma, Inc. | 2 | $31 |
| Medtronic | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| GRT US Holding, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,050
- SOLIQUA 100/33$400
- NO PRODUCT DISCUSSED$375
- Repatha$125
- Tirosint$125
- Vascepa$125
- Tymlos$122
- AFREZZA$115
- EVENITY$102
How this compares
$5,689 in reported general payments places this provider in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Other endocrinology, diabetes & metabolism in Plano
- Rosemarie LajaraPlano$1.2M
- Mitchell SorsbyPlano$945K
- Heidi SheaPlano$186K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.